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Background: The antitumor drug nilotinib has a large inter- and intra individual variability in pharmacokinetics.
Adherence to treatment may substantially influence plasma levels and has been recognized as the most important
determinant of treatment failure in chronic myeloid leukemia (CML). A better understanding of the various factors
contributing to the efficacy of treatment is essential for the development of interventions to optimize the treatment
of chronic phase CML (CP-CML) with a protein kinase inhibitor like nilotinib.
Methods/Design: In this multicenter prospective observational cohort study 70 adult patients with CP-CML starting
treatment with nilotinib will be followed up for at least 12 months. Response to treatment is evaluated after 3, 6
and 12 months. Adherence is primarily assessed by counting the daily intake of nilotinib capsules by means of a
medication event monitoring system (MEMS). Before the start of nilotinib treatment and after 3, 6 and 12 months,
patients are asked to fill in a comprehensive questionnaire including topics on quality of life, side effects, attitude
towards disease and medication, the patients’ appreciation of information received about the medication, and
discontinuation, and trough plasma levels of nilotinib are measured.
Discussion: The present study aims to get more insight into the efficacy of treatment with nilotinib and the
various aspects that govern optimal response, of which adherence is a primary endpoint. We hypothesize that
patients who experience inadequate response levels to nilotinib are less adherent. In addition, their plasma levels
of nilotinib may be lower. We expect that our findings will be useful for health care professionals to support
patients with the use of nilotinib in order to derive optimal benefit from their medication.
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Chronic myeloid leukemia (CML) is a malignant disease
in which too many white blood cells belonging to the
myeloid line of cells are produced in the bone marrow.
CML is due to the growth and evolution of an abnormal
clone of cells containing a chromosome rearrangement
known as the Philadelphia chromosome (Ph+ cells). In
the Ph chromosome a part of the BCR (‘breakpoint clus-
ter region’) gene from chromosome 22 is fused with the
ABL (‘Abelson leukemia virus’) gene on chromosome 9.
The oncogenic BCR-ABL fusion gene encodes the BCR-
ABL fusion protein. As a protein kinase it causes mye-
loid white blood cells to multiply uncontrollably [1].
Treatment of early or chronic phase Ph+ CML (CP-
CML) with tyrosine kinase inhibitors (TKI) like imatinib
results in very high response and survival rates [2]. Un-
fortunately, a considerable number of patients does not
achieve adequate response levels and is at risk for dis-
ease progression. Causes of this lack of response include
the presence of point mutations in the kinase domain of
the BCR-ABL protein, increased expression of the BCR-
ABL fusion gene and increased drug efflux mechanisms.
Pharmacokinetic factors leading to suboptimal drug
plasma concentrations may also affect the treatment re-
sult [3]. However, poor adherence to imatinib has now
been recognized as the most important determinant of
treatment failure [4-7]. The detrimental effect of poor
adherence may be falsely interpreted as the development
of resistance to TKI treatment. Reasons underlying poor
adherence include the development of (serious) adverse
effects, long duration of treatment and the absence of
symptoms of the disease [8,9]. Resistance to imatinib as
related to BCR-ABL point mutations has been largely
overcome by using the 2nd generation TKIs dasatinib
and nilotinib [10,11]. Although data on long-term treat-
ment results are not yet available, 2nd generation TKIs,
especially nilotinib, have been shown to be more effec-
tive than imatinib in first line therapy in attaining im-
portant endpoints as a complete cytogenetic response
(CCyR), i.e. the absence of Ph+ cells in blood and bone
marrow and a major molecular response (MMR), i.e. the
near absence of BCR-ABL fusion mRNA transcripts
(a reduction to ≤0.1% on the international scale) [12,13].
The latter endpoint is strongly predictive for long-term
event-free survival [14]. First-line use of these TKI is
therefore now recommended for intermediate and high
risk patients [10,11]. On average, an MMR is attained at
least one year earlier with the 2nd generation TKIs as
compared to imatinib [14,15].
A better understanding of the various factors contrib-
uting to the efficacy of treatment is essential for the
development of interventions to optimize CP-CML
treatment with a TKI. In the present study nilotinib
treatment with the standard dose (300 mg twice daily) ofpatients with CP-CML is monitored as recommended by
the current Dutch treatment guideline [10]. At present,
treatment of CP-CML patients aims to achieve a lasting
CCyR and MMR. However, on the basis of the more
rapid onset of its effect than of imatinib [13], treatment
with nilotinib could already result in a CCyR and MMR
within 6 and 12 months after the start of treatment, re-
spectively, instead of 12 and 18 months as stated in the
guideline [10].
The present study aims to get more insight into the ef-
ficacy of treatment with nilotinib and the various aspects
that govern optimal response, of which adherence is a
primary endpoint. Adherence is primarily assessed by
counting the daily intake of nilotinib capsules using a
medication event monitoring system (MEMS). Patient
experiences with drug use is assessed by means of a
comprehensive questionnaire including topics on quality
of life, side effects, attitude towards disease and medica-
tion, and the patients‘ appreciation of information re-
ceived about the medication. Response to treatment is
related to nilotinib trough plasma concentrations [16].
In contrast to venous puncture as used to obtain suffi-
cient blood to evaluate efficacy, the Dried Blood Spot
(DBS) sampling method requires only a very small quan-
tity of blood that is obtained by means of a finger prick.
Particularly at early stages of treatment this convenient
and simple method is an ideal means to detect subopti-
mal nilotinib plasma concentrations that may occur as
a result of non-adherence to treatment or drug-drug
interactions.
Objectives
The primary objective of the RAND-study (Response
and Adherence to Nilotinib in Daily practice) is to assess
whether CP-CML patients who respond to treatment
with nilotinib (MMR within 12 months of treatment)
differ from the non-responders in terms of adherence.
Secondary objective is to evaluate whether responders
and non-responders to nilotinib (molecular response
after 3, 6 and 12 months of treatment) differ with re-
spect to their plasma levels of nilotinib. Furthermore,
the study aims to identify possible predictors for
response to nilotinib treatment among hypothesized
predictors that include occurrence of side effects, adher-
ence, nilotinib blood levels, quality of life, attitude to-
wards disease, beliefs and attitude towards medicines,
patients‘ appreciation of information received about the




The study is designed as a multicenter prospective
observational cohort study. CP-CML patients starting
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12 months as required to establish full cytogenetic re-
sponses in a relevant number of patients [10,14,15]. The
study will end when the last patient has been followed
for 12 months. In case of failure of treatment with niloti-
nib, treatment will be changed according to the guide-
line. Nilotinib treatment comprises the standard daily
dose of nilotinib (300 mg twice daily) [3].
Study population
The study population consists of 70 adult CP-CML pa-
tients starting treatment with a 2nd generation TKI i.c.
nilotinib.
Study parameters
The primary research question is the comparison of
patients responding to nilotinib treatment to the non-
responders in terms of adherence. Response to nilotinib
treatment is defined as presence of a MMR within
12 months after the start of first study medication.
MMR is defined as ≤ 0.1% BCR-ABL/ABL (or any other
validated house keeping gene) in the international scale,
as measured by real-time quantitative PCR (RQ-PCR)
[10]. The primary means of assessing adherence is the
total intake of nilotinib capsules as counted by means of
a MEMS taken as percentage of the number of pills pre-
scribed over the 12 months follow-up period.
Secondary parameters include: rates of complete
hematological response (CHR; the normalization of
the blood cell count), CCyR (complete absence of Ph
+ cells in blood and bone marrow), and complete mo-
lecular response (CMR)(using RQ-PCR Ph +DNA cannot
be detected); trough plasma level of nilotinib; potential
drug-drug interactions; patient-reported side effects; ad-
herence by means of telephonic pill count; adherence be-
haviour by means of the Medication Adherence Rating
Scale (MARS); quality of life by means of the SF-12 Health
Survey; attitude towards disease and medication by means
of the Brief Illness Perception Questionnaire (IPQ) and
the Beliefs about Medicines questionnaire (BMQ), resp.;
patients‘ appreciation of information received about the
medication by means of the Satisfaction with Information
about Medicines Scale (SIMS); percentage of dose




After 3, 6 and 12 months of nilotinib treatment, patients
are asked to provide blood samples by finger prick.
Blood sampling will take place at the patient‘s home just
before taking the next dose of nilotinib in order to ob-
tain trough levels. Data on the exact time of administra-
tion of the previous dose are collected. Finger prickblood samples are collected using an automatic lancet
device. Samples are collected from the fingertip. The
first drop is discarded and the next 2 drops are collected
to fill 2 8-mm premarked circles on the sampling
paper (Whatman™, FTA™ DMPK-C (GE Healthcare),
WB129243, obtained from VWR International BV,
Amsterdam, The Netherlands). Volume of the blood
drops of patients will be approximately 30 μl and blood
spots of about 10-mm diameter are produced. The blood
spots are allowed to dry at room temperature and
packed in sealable plastic minibags. The DBS samples
solely serve to monitor nilotinib blood levels. DBS sam-
ples are analyzed according to a recently developed
method [17,18]. More detailed description of the analysis
of DBS samples has been published elsewhere [17,18].
No other invasive intervention is performed for the
present study. Response to treatment is regularly evalu-
ated for treatment purposes in peripheral blood obtained
by venapuncture and/or bone marrow after 3, 6 and
12 months of treatment. The results of the response to
treatment are collected in the Case Report Form. Be-
cause Larson et al. [19] found that the occurrence of all-
grade elevations in total bilirubin and to a lesser extend
also of elevations in aspartate transaminase (ASAT) were
higher in patients with higher nilotinib exposure, these
parameters are determined as safety parameters at the
same time as the regularly withdrawn venous blood sam-
ples for the measurement of response. The results of
total bilirubin and ASAT are collected in the Case Re-
port Form after 3, 6 and 12 months of treatment.Pill count
Adherence is primarily assessed by counting the daily in-
take of nilotinib capsules by means of a MEMS, which is
a microchip hidden in the lid of a medication box. Sec-
ondary assessment of adherence is by means of a tele-
phonic pill count. Patients are contacted unannounced
by the researcher by phone at the end of the 12 months
follow-up period to count the number of remaining cap-
sules at home. The count is performed using a standard-
ized interview protocol. Pharmacy medication records
and data on drug prescription in the medical file of the
patient will be assessed. The total amount used by the
patient is calculated by subtracting the amount in stock
or returned to the pharmacy from the total amount
collected from the pharmacy. The adherence rate is
expressed as the percentage of drug taken by the patient
of the total amount prescribed [20].Review of the pharmacy medication records
The total number of delivered capsules, dose in milligram
(mg) and dosing regimen of nilotinib is collected from
the outpatient pharmacy of the hospital. Furthermore,
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collected for data on co-medication.
Review of the patient‘s medical file
Information on the disease, treatment plan and prescribed
number of capsules, including dose, dose adjustments,
(temporary) discontinuation or any other deviation from
the prescribed treatment is retrieved from the patient‘s
medical file.
Patient questionnaires
Before the start of nilotinib treatment and after 3, 6 and
12 months, patients are asked to fill in a comprehensive
questionnaire on patients‘ experience with the use of
nilotinib and their opinion on DBS. The questionnaire at
baseline includes the factors date of birth, gender, living
status, socio-economic status, non-prescription medica-
tion, quality of life, attitude towards disease and medica-
tion, and the side effects already perceived by the patient
at baseline. The questionnaire at 3, 6 and 12 months
includes non-prescription medication, quality of life,
attitude towards disease and medication, side effects, ad-
herence by means of the MARS, the patients‘ appreci-
ation of information received about the medication,
discontinuation and questions upon experiences with
and opinions on the DBS. The following validated ques-
tionnaires will be used:
– MARS: a validated self-report method to assess
adherence behaviour. The MARS has five adherence
statements, each scored on a 5-point Likert scale.
This questionnaire assesses the frequency of
non-adherent behaviour [21,22].
– SF-12: quality of life is assessed with the SF-12
Health Survey. The SF-12 is a short version of the
SF-36 and is a validated method to assess quality of
life. The SF-12 is composed of 12 questions and
standardized response choices, organized into eight
scales: physical functioning, role limitations due to
physical health problems, bodily pain, general health
perceptions, vitality, social functioning, role limita-
tions due to emotional problems, and general mental
health. The standardized response choices vary
dependent on the question from a five-item scale
of always to never or a dichotomous scale from
yes to no [23,24].
– IPQ: a validated method to measure the attitude
towards disease. The Brief IPQ consists of one open
item and nine items on a continuous linear scale
from 0 to 10 to assess perceptions. It assesses
cognitive illness representations, emotional
representations and illness comprehensibility [25].
– BMQ: a validated questionnaire to assess beliefs and
attitude towards medication. The BMQ consists oftwo five-item scale parts, the BMQ general and
the BMQ specific. It assesses patients‘ beliefs and
attitude towards the necessity of prescribed
medication for controlling their disease and their
concerns about potential adverse consequences of
taking it. BMQ general measures the patients‘ beliefs
and attitude towards medication in general. In the
BMQ specific this is specified for the studied agent [26].
– SIMS: the patients‘ appreciation of information
given by physician/pharmacist/nurse practitioner
about the medication is assessed with the SIMS
questionnaire. The SIMS questionnaire is a validated
method to assess the extent to which patients
consider themselves (adequately) informed about
their prescribed medication on a five-item scale [22].
Ethical matters
The study is conducted according to the principles of
the declaration of Helsinki (2008) and the Medical Re-
search Involving Human Subjects Act (WMO), and
has been approved by the Medical Research Ethics
Committee (MREC) of the VU University Medical Cen-
ter, Amsterdam, The Netherlands. In addition, the study
has received approval for patient recruitment at the
University Medical Center Utrecht, Medisch Spectrum
Twente Enschede, University Medical Center Groningen,
and Albert Schweitzer Hospital Dordrecht. Written in-




In [6] a difference in nonadherence, measured as per-
centage of pills not taken of number prescribed, of
15.9% was found (mean nonadherence was 7.3% in re-
sponders and 23.2% in the non-responders) and the
standard deviation of nonadherence was approximately
21.5%. Based on these numbers, the study described here
is powered to detect a difference in mean adherence of
three-quarters of the standard deviation. Under the as-
sumption that adherence is normally distributed and 50
percent of the patients show a response, a total of 58 pa-
tients will yield 80% power to detect a difference of this
size by means of an independent sample t-test and
two-sided testing at a significance level of 5%. In case 60
percent of the patients show a response a total of 65 pa-
tients are needed. The sample size is set at 70 to take
into account this uncertainty in number of patients
responding and a small number of patients that become
lost to follow-up.
Statistical analyses
Data will be analysed using SPSS 20.0 for Windows
(SPSS Inc. Chicago, Illinois, USA). Baseline descriptive
Boons et al. BMC Cancer 2014, 14:247 Page 5 of 6
http://www.biomedcentral.com/1471-2407/14/247statistics will be presented as means (standard devia-
tions) for normally distributed continuous data, medians
and inter-quartile ranges for skewed continuous vari-
ables and as frequencies (percentage) for categorical var-
iables. The primary objective is to compare adherence
(percentage pills taken of those prescribed) between the
responders and non-responders. In case, the normality
assumption holds, this will be tested by an independent
sample t-test. In case of skewed distribution for adher-
ence, the non-parametric Mann–Whitney test will be
used instead. Plasma level of nilotinib will be compared
between responders and non-responders in the same
manner. For the explorative assessment of predictors for
response, we will use separate logistic regression models
for each predictor. Logistic regression will also be used
to identify possible confounders for adherence. Only the
strongest predictors will be tested as confounding vari-
ables. Confounding variables are added as independent
variables to the model relating response (dependent
variable) to adherence (independent variable). Con-
founders are considered one-at-a-time as the number
of patients falling in the smallest outcome category
(of non-responders) is expected to include only between
20 and 30 patients, thereby adhering to the ten-event-
per variable rule for logistic regression. For all analyses a
two tailed significance level will be 0.05, all p-values
below this level are considered statistically significant.
Discussion
The present study is conducted to prospectively evaluate
the relationship between the efficacy of treatment with
nilotinib and adherence to treatment in CP-CML pa-
tients. We expect variability in adherence among the
participating CP-CML patients. The evaluation of the in-
fluence of this adherence-variation on response may be
complicated by inter-patient variability in pharmacoki-
netics of nilotinib. We hypothesize that patients who
show a reduced molecular response to nilotinib are less
adherent. In addition, these patients may have lower
plasma levels of nilotinib. To obtain more insight into
factors related to the efficacy of treatment, the effects of
determinants are studied in an explorative manner. Es-
pecially, side effects may influence adherence, persis-
tence and dose adjustments, and may thereby result in a
reduced response. Furthermore, factors like beliefs about
disease and medication or satisfaction upon information
may influence adherence. The examination of these fac-
tors and patients‘ experiences with the DBS-method will
give a broad insight into the use of nilotinib from the pa-
tients‘ point of view.
To date, no study has prospectively examined the in-
fluence of non-adherence on the outcome of nilotinib in
CML. We expect that this study will provide valuable
knowledge which will be useful for health careprofessionals to support patients with the use of niloti-
nib in order to obtain optimal response to nilotinib in
daily practice.
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